When AI starts making decisions, pharma has to rethink the operating model
The harder question for pharmaceutical companies is no longer where AI can be deployed. It is where technology can be allowed to influence a decision, how much authority it should have and whether a human can still explain why that decision was made.
That distinction is becoming increasingly important as AI moves from analysing information to acting on it. For Sowjanya Varma, CIO at HRV Pharma, this marks a fundamental departure from earlier enterprise technology cycles. Previous transformations largely helped people perform existing tasks faster. AI, she argues, is beginning to change the nature of the decision itself.
“All our previous transformations were largely about helping people do what they’ve already done before,” Varma says. “When it comes to AI, it is slightly different because it can actually participate in the decision making process.”
For a pharmaceutical business, that distinction carries particular weight. The industry operates across products, suppliers, markets...
Copyright of this story solely belongs to www.expresscomputer.in. To see the full text click HERE
